Skip to main content
Delfa

← All assets

Donanemab

16 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

16

Ongoing

11

Recruiting

4

Completed

5

Sites

670

Countries

15

Endpoints

212

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 212 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
2
Phase 2
4
Phase 2/3
1
Phase 3
7
Phase 4
1
Not applicable
1

Trials by status

Not yet recruiting
2
By invitation
1
Recruiting
4
Active, not recruiting
4
Completed
5

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Amyloid biomarkers
60
Global cognition
43
Other (unclassified)
32
Safety / tolerability / PK
30
Function / daily living
18
Neuroimaging
9
Disease progression
8
Tau biomarkers
7
Memory
2
Caregiver / quality of life
2
Behavior / neuropsychiatric
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 101 of 212 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Amyloid PET CentiloidAmyloid

45

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

14

ADAS-CogCognition

12

Mini-Mental State Examination (MMSE)Cognition

9

ADAS-CogFunction

6

ADCS-Activities of Daily Living (ADCS-ADL)Function

6

Phosphorylated tau 217 (p-tau217)Tau

2

Phosphorylated tau 217 (p-tau217)Amyloid

2

ADAS-CogOther

2

Montreal Cognitive Assessment (MoCA)Cognition

1

Phosphorylated tau 217 (p-tau217)Other

1

Neuropsychiatric Inventory (NPI)Behavior

1

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

16 of 16

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT04437511A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

Donanemab

Alzheimer’s disease

MMSE 20-28Ph 3Active, not recruiting274Apr 202313results
NCT05026866A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Donanemab

Alzheimer’s disease

Amyloid biomarker requiredPh 3Active, not recruiting216Nov 20271
NCT05508789A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Donanemab

Alzheimer’s disease

MMSE 20-28Ph 3Active, not recruiting141May 2028-
NCT07589595A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

Donanemab

Lewy body dementia

Dementia with Lewy bodiesPh 2Recruiting72Aug 2028-
NCT03367403A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

Donanemab, LY3202626

Alzheimer’s disease

MMSE 20-28Ph 2Completed61Dec 20208results
NCT07602582A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

Donanemab

Alzheimer’s disease

Study partner/caregiver requiredPh 3Recruiting59Sep 2029-
NCT05738486A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

Donanemab

Alzheimer’s disease

Amyloid biomarker required (PET)Ph 3Active, not recruiting49May 20242results
NCT05108922A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

Aducanumab, Donanemab

Alzheimer’s disease, MCI / preclinical Alzheimer’s

MMSE 20-30Ph 3Completed31Sep 20222results
NCT07571161Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease

Donanemab

Alzheimer’s disease

Amyloid biomarker required (plasma)Ph 3Recruiting30Apr 2030-
NCT04640077A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

Donanemab

Alzheimer’s disease

Study partner/caregiver requiredPh 2Completed27Feb 20242results
NCT02624778A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

Donanemab

Alzheimer’s disease, MCI / preclinical Alzheimer’s

mild-to-moderate ADPh 1Completed9Aug 20191results
NCT01837641A Study of LY3002813 in Participants With Alzheimer's Disease

Donanemab

Alzheimer’s disease, MCI / preclinical Alzheimer’s

MCI due to AD / mild-to-moderate ADPh 1Completed6Aug 2016-results
ATPAlzheimer's Tau Platform: Regimen A - AADvac1

AADvac1, Donanemab

Alzheimer’s disease

Age 50-80Ph 2By invitation1Aug 2028-
NCT06996730A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease

Donanemab, RG6289

Alzheimer’s disease

mild AD dementia · PSEN1 mutation requiredPh 2/3Not yet recruiting1Jun 2030-
NCT06566170A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

Donanemab

Alzheimer’s disease

Alzheimer's diseaseNot applicableRecruiting1Feb 2033-
ALADDINAmyloid Lowering for Alzheimer's in Down's With Donanemab Investigation

Donanemab

Alzheimer’s disease

Amyloid biomarker requiredPh 4Not yet recruiting0Dec 2028-

Showing 1-16 of 16 trials